A global biopharmaceutical company focused on developing medicines for sleep disorders, epilepsy, and cancer, with strong 2024 sales growth and ongoing oncology and neuroscience clinical programs.

# Company Summary

## Business Overview
- **Type:** Global biopharmaceutical company  
- **Purpose:** To innovate and transform the lives of patients and their families by developing life-changing medicines for serious diseases.  

## Product Portfolio
- **Marketed Medicines:**  
  - Therapies for sleep disorders and epilepsy  
  - Growing portfolio of cancer treatments  
- **Pipeline Focus:** Oncology and neuroscience therapeutics  

## Business Strategy
- **Growth Focus:**  
  - Launching and commercializing new medicines  
  - Advancing robust R&D programs with impactful clinical results  
  - Strategic corporate development to support long-term goals  
  - Delivering strong financial performance  
- **Target Patient Populations:** Those with high unmet medical needs  
- **Operational Model:** Highly efficient, scalable, and global infrastructure to reach patients worldwide  

## 2024 Performance Highlights
- **Revenue Growth Drivers:**  
  - Strong sales of marketed therapies including Xywav®, Epidiolex®, Rylaze®  
  - Launch of Ziihera for unresectable/metastatic HER2-positive biliary tract cancer (BTC) in the U.S.  
- **2024 Product Sales:**  
  - Xywav: $1,473.2 million (up 16%)  
  - Epidiolex/Epidyolex: $972.4 million (up 15%)  
  - Rylaze: $410.8 million (up 4%)  
  - Zepzelca: $320.3 million (up 11%)  
- **Pipeline Milestones:**  
  - Approved and launched zanidatamab (Ziihera) for BTC based on positive trial data and FDA accelerated approval in November 2024  
  - Initiated and advanced multiple trials in HER2-positive cancers, ET, PDT, and SCLC  
  - Declined primary endpoint results for some trials but achieved significant benefits in others  

## Customer Base and Operations
- Exact number of customers or patients treated is not provided.  
- Employees: Not specified in the summary provided.  

## Financial Data
- **Total Revenue for 2024:** Not explicitly disclosed.
- **Net Product Sales (select therapies):**  
  - Xywav: $1,473.2 million  
  - Epidiolex/Epidyolex: $972.4 million  
  - Rylaze: $410.8 million  
  - Zepzelca: $320.3 million  
- **Income or profit figures:** Not provided in the summary.  

## Summary
The company is a leader in developing and marketing medicines for sleep disorders, epilepsy, and cancer, with a focus on high unmet medical needs. It experienced strong sales growth in 2024, launched a new cancer therapy, and advanced multiple clinical programs across oncology and neuroscience, aiming to drive long-term growth and innovation globally.

Jazz Pharmaceuticals is a global biopharmaceutical company focused on developing innovative treatments in neuroscience and oncology for patients with serious diseases.

# Company Overview: Jazz Pharmaceuticals Public Limited Company

**Business Summary:**

Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to innovating and transforming the lives of patients by developing life-changing medicines for serious diseases. The company's primary focus areas include:

- **Neuroscience**: 
  - Leading therapies for sleep disorders (e.g., Xywav for narcolepsy and idiopathic hypersomnia).
  - Child and adolescent epilepsy management (e.g., Epidiolex).

- **Oncology**: 
  - Cancer treatment portfolio, which includes drugs like Rylaze and Zepzelca.

**Key Highlights:**

- **Employees**: The company employs approximately 1,400 employees globally.

- **Number of Customers**: Jazz Pharmaceuticals serves a broad patient population, specifically targeting individuals with serious diseases often lacking effective therapeutic options. While exact customer numbers are not disclosed, the broad reach across multiple markets indicates a substantial user base.

- **Financial Performance**:
  - **Total Revenue**: For the fiscal year ended December 31, 2023, total revenues were approximately **$3.83 billion**, a 5% increase compared to the previous year.
  - **Net Income**: The company reported a net income of approximately **$415 million**, translating to **$6.10 per diluted share**, compared to a net loss of **$224 million** in 2022.

- **Product Portfolio**: Jazz Pharmaceuticals boasts a diverse range of marketed products and a robust pipeline aimed at addressing high unmet medical needs.

**Strategic Focus**:
The company emphasizes a **patient-focused and science-driven approach**, aiming for sustainable growth through:
- Advancing robust research and development programs.
- Successful commercialization initiatives.
- Strategic corporate development to enhance long-term shareholder value.

**Vision 2025**: Jazz Pharmaceuticals has set forth a strategic plan known as Vision 2025, which aims to deliver sustainable growth and enhance value by focusing on commercial execution, pipeline productivity, and operational excellence.

By combining an innovative approach with a strong commitment to improving patient outcomes, Jazz Pharmaceuticals continues to position itself as a high-growth leader in the pharmaceutical industry.

Jazz Pharmaceuticals plc

10-K / April 25, 2025

10-K / April 26, 2024

10-K / April 25, 2025

Company Summary

Business Overview

Product Portfolio

Business Strategy

2024 Performance Highlights

Customer Base and Operations

Financial Data

Summary